Suven Life Sciences reports positive Phase-2b trial results for Ropanicant

Suven Life Sciences reports positive Phase-2b trial results for Ropanicant. Company announced positive topline results from its Phase-2b proof-of-concept trial of Ropanicant in Major Depressive Disorder. The drug candidate showed statistically significant improvement over placebo with p-value <0.05. This success may accelerate development plans and boost investor confidence in the pipeline.

📊 STOCKS: SUVENLIFE | 🏢 SECTOR: Pharma | #HIGHIMPACT #ClinicalTrial